{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-25-000049","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.695624+00:00","generated_at":"2026-05-16T23:20:19.203314+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lexicon Q3 2025 net loss narrows to $12.8M; pipeline advances with FDA milestones on track","bullets":["Q3 revenue $14.2M (from $1.8M YoY) driven by $13.2M Novo Nordisk licensing; net loss $12.8M vs $64.8M prior year.","Cash and investments $145M as of Sep 30, down from $238M at Dec 31, 2024, but company says strong footing.","End-of-Phase 2 meeting for pilavapadin (DPNP) with FDA scheduled by year-end; partnership discussions ongoing.","LX9851 IND-enabling studies completed and handed to Novo Nordisk; near-term milestone potential $30M.","SONATA-HCM Phase 3 enrollment on target for 2026; 130 sites initiated. Zynquista resubmission feedback expected Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-25-000049","json":"https://secwatch.observer/filing/0001062822-25-000049.json","markdown":"https://secwatch.observer/filing/0001062822-25-000049.md","text":"https://secwatch.observer/filing/0001062822-25-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282225000049/0001062822-25-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282225000049/lxrx-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:20:19.203314+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}